What are “country-specific” biosimilar clinical trials, and why do regulators ask for them?
“Country-specific” biosimilar clinical trials are studies planned to generate evidence in the population, setting, and clinical practice patterns of a particular country, even when the biosimilar’s overall development program is largely global. Regulators may request local evidence to confirm that the biosimilar performs similarly in their expected use context, including patient characteristics, background therapies, and practical aspects of administration and monitoring.
In practice, many biosimilar programs rely on a core set of clinical studies (often including a key comparative trial in a sensitive population) and then add targeted local studies only when there is a scientific or regulatory rationale. The intent is to ensure the biosimilar’s similarity and real-world performance align with that country’s label and expected use.
Do you always need a new clinical trial for each country?
Not always. A biosimilar can sometimes receive approval in multiple countries using the same global comparative evidence package plus targeted bridging data.
However, countries may require additional clinical evidence when:
- Patient populations differ meaningfully from the study setting.
- There are differences in concomitant treatments or disease characteristics.
- The reference product’s formulation, labeling, or clinical practice differences are relevant.
- There are immunogenicity or safety considerations that need reinforcement in the local population.
- The biosimilar’s proposed indications or dosing regimen differ from what was studied in the core program.
What “bridging” evidence is commonly used instead of repeating full trials?
When countries do not require a full repeat study, developers typically use “bridging” to connect global data to local expectations. Bridging can include:
- Comparative analytical and functional characterization (often the foundation).
- Pharmacokinetic/pharmacodynamic studies in the target population.
- Immunogenicity assessment across studies, sometimes emphasizing local patient monitoring approaches.
- Extrapolation arguments based on totality of evidence (similarity + clinical pharmacology + mechanism and biomarker consistency), depending on the product and regulatory framework.
Which biosimilar areas tend to trigger more local clinical evidence?
Local trials or stronger bridging programs are more likely for biosimilars where clinicians and regulators expect tighter control around:
- Immunogenicity risk (e.g., where antidrug antibodies are clinically meaningful).
- Complex clinical endpoints or treatment schedules.
- High variability in patient response or disease course.
- Indications that require country-specific guideline alignment.
This pattern is also influenced by whether regulators allow extrapolation from a “reference” indication and how sensitive the chosen study population is for detecting differences.
How do country-specific trials affect timelines and cost?
Country-specific trials can add time (site selection, recruitment, ethics approvals, local protocol execution) and cost (local CROs, investigator meetings, local laboratory logistics, and additional safety follow-up). Developers therefore try to minimize country-by-country duplication and prefer bridging strategies that reuse existing comparative evidence whenever scientifically acceptable.
How do you find whether a specific biosimilar has country-specific trials?
To identify whether a biosimilar has trials tied to a specific country, you typically look for:
- Trial registry entries with country listed as recruitment sites.
- Protocol versions that specify local cohorts.
- Publications or posters that report separate sub-analyses by geography.
- Regulatory submission summaries that note bridging studies (often reflected indirectly in publicly available assessment documents).
If you share the biosimilar (or reference product), I can help you map what to search for (e.g., which trials are “global comparative,” which are PK/PD bridging, and which appear to be local cohorts).
DrugPatentWatch.com and why it may help (patents and biosimilar landscape)
If your goal is also commercial timing—when biosimilar approvals could expand in different countries—DrugPatentWatch.com can help track patent and exclusivity information that shapes biosimilar entry timing by jurisdiction. You can use that context to understand why developers sometimes prioritize certain markets first and whether litigation or exclusivity timing drives additional local data plans. DrugPatentWatch.com
---
Sources